Equillium (EQ) Total Non-Current Liabilities (2017 - 2026)
Equillium's (EQ) quarterly Total Non-Current Liabilities came in at $3.6 million in Q1 2026, down 41.54% year-on-year from $6.2 million in Q1 2025, and up 9.3% on a QoQ basis from $3.3 million in Q4 2025.
Equillium (EQ) Total Non-Current Liabilities (2017 - 2026) Analysis & Trends
Equillium (EQ) has 10 years of Total Non-Current Liabilities data on file, last reported at $3.6 million in Q1 2026.
- On a quarterly basis, Total Non-Current Liabilities fell 41.54% year-over-year to $3.6 million in Q1 2026; TTM through Mar 2026 was $3.6 million, a 41.54% decrease from a year earlier, with the FY2025 full-year figure at $3.3 million, down 49.72% from the prior year.
- Total Non-Current Liabilities for Q1 2026 stood at $3.6 million, up from $3.3 million in the prior quarter.
- Over the last five years, Total Non-Current Liabilities for EQ reached as high as $46.5 million in Q4 2022 and fell as low as $3.3 million in Q4 2025.
- Historically, Total Non-Current Liabilities has averaged $19.3 million across 5 years, with a median of $20.5 million in 2022.
- Across the five-year window, Total Non-Current Liabilities soared 145.92% in 2022 and slumped 76.6% in 2024, its largest moves.
- Year by year, Total Non-Current Liabilities stood at $46.5 million in 2022, then plunged by 39.85% to $28.0 million in 2023, then slumped by 76.6% to $6.5 million in 2024, then sank by 49.72% to $3.3 million in 2025, then gained by 9.3% to $3.6 million in 2026.
- Per Business Quant data, the three most recent Total Non-Current Liabilities figures were $3.6 million in Q1 2026, $3.3 million in Q4 2025, and $3.6 million in Q3 2025.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | 4.45 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | 110.28 Mn |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | 19.49 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 1.98 Bn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 5.87 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 7.32 Bn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | - |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | - |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | 746.94 Mn |
| 10 | Equillium | 242.14 Mn | 242.14 Mn | - | 3.60 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 3.60 Mn |
| Dec 31, 2025 | 3.29 Mn |
| Sep 30, 2025 | 3.57 Mn |
| Jun 30, 2025 | 7.34 Mn |
| Mar 31, 2025 | 6.15 Mn |
| Dec 31, 2024 | 6.54 Mn |
| Sep 30, 2024 | 11.28 Mn |
| Jun 30, 2024 | 20.43 Mn |
| Mar 31, 2024 | 22.50 Mn |
| Dec 31, 2023 | 27.96 Mn |
| Sep 30, 2023 | 31.12 Mn |
| Jun 30, 2023 | 31.78 Mn |
| Mar 31, 2023 | 42.52 Mn |
| Dec 31, 2022 | 46.48 Mn |
| Sep 30, 2022 | 20.47 Mn |
| Jun 30, 2022 | 22.21 Mn |
| Mar 31, 2022 | 21.61 Mn |
| Dec 31, 2021 | 18.90 Mn |
| Sep 30, 2021 | 16.65 Mn |
| Jun 30, 2021 | 15.05 Mn |